{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:15:39Z","timestamp":1768997739927,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Genetics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.cancergen.2019.07.008","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T11:43:32Z","timestamp":1563968612000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"238","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7597-2037","authenticated-orcid":false,"given":"Hongyu","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derek","family":"Lyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paris","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Drum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie-Gen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergen.2019.07.008_bib0001","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0002","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0003","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0004","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0005","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/cncr.22936","article-title":"The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells","volume":"110","author":"Deininger","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0006","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12032-012-0443-1","article-title":"Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia","volume":"30","author":"Bozkurt","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0007","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","article-title":"Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"110","author":"Jabbour","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cancergencyto.2010.02.005","article-title":"Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells","volume":"199","author":"Larsson","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0009","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0301-472X(03)00176-0","article-title":"The emergence of Ph-, trisomy-8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"31","author":"Feldman","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0010","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissue","first-page":"32","article-title":"Chronic myelogenous leukemia BCR-ABL1 positive","author":"Vardiman","year":"2008"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000353118","article-title":"Cytogenetic Nomenclature: changes in the ISCN 2013 compared to the 2009 edition","volume":"141","author":"Simons","year":"2013","journal-title":"Cytogenet Genome Res"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0012","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/(SICI)1098-2264(200001)27:1<11::AID-GCC2>3.0.CO;2-I","article-title":"Clinical significance of y chromosome loss in hematologic disease","volume":"27","author":"Wiktor","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0013","first-page":"1","article-title":"Acute myeloid leukemia developed in Ph-\u2009cells with MLL gene amplification in a patient with chronic myelogenous leukemia","volume":"23","author":"Jiang","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0014","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment","volume":"130","author":"Issa","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cancergencyto.2010.08.017","article-title":"Factors influencing a second myeloid malignancy in patients with Philadelphia-negative -7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia","volume":"204","author":"Groves","year":"2011","journal-title":"Cancer Genet"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0016","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/386732a0","article-title":"Functional interaction between DNA-PK and c-Abl in response to DNA damage","volume":"386","author":"Kharbanda","year":"1997","journal-title":"Nature (Lond)"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0018","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/sj.leu.2403861","article-title":"Induction of centrosome and chromosome aberrations by imatinib in vitro","volume":"19","author":"Fabarius","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0019","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.cancergencyto.2010.02.003","article-title":"Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications","volume":"199","author":"Zaccaria","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0020","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph\u2212 cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0021","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0022","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1038\/bcj.2016.18","article-title":"A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML","volume":"6","author":"Krysiak","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0023","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.mad.2012.05.007","article-title":"Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment","volume":"133","author":"Lobetti-Bodoni","year":"2012","journal-title":"Mech Ageing Dev"},{"key":"10.1016\/j.cancergen.2019.07.008_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergen.2017.04.066","article-title":"Clonal chromosomal aberrations in Philadelphia negative cells such as monosomy 7 and trisomy 8 may persist for years with no impact on the long term outcome in patients with chronic myeloid leukemia","volume":"216\u2013217","author":"Wasilewska","year":"2017","journal-title":"Cancer Genet"}],"container-title":["Cancer Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776218305568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210776218305568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:42:39Z","timestamp":1761896559000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210776218305568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":24,"alternative-id":["S2210776218305568"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergen.2019.07.008","relation":{},"ISSN":["2210-7762"],"issn-type":[{"value":"2210-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implications of clonal chromosomal abnormalities in Philadelphia negative cells in CML patients after treated with tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cancer Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cancergen.2019.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}